Skip to content

Effect of Myrtus Communis L. (Myrtle) syrup in patients with chronic rhinosinusitis

Evaluation the effect of Myrtus Communis L. (Myrtle) syrup in patients with chronic rhinosinusitis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016020926465N1
Enrollment
60
Registered
2016-03-03
Start date
2016-02-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic rhinosinusitis. Other chronic sinusitis (chronic) involving more than one sinus but not pansinusitis

Interventions

Intervention 1: Control group: placebo syrup/ 5 cc/ twice daily/30 days. Intervention 2: Intervention group: myrtle syrup 3%/ 5 cc/ twice daily/ 30 days.
Placebo
Treatment - Drugs
Control group: placebo syrup/ 5 cc/ twice daily/30 days
Intervention group: myrtle syrup 3%/ 5 cc/ twice daily/ 30 days

Sponsors

Vice Chancellor for research, Shahid Sadoughei University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with chronic rhinosinusitis; over 18 years old; who come to the Masih Daneshvari hospital; Patients who suffer from rhinosinusitis symptoms for more than three months; Patients with chronic rhinosinusitis according to lund McKay scale criteria approved by an expert; Patients who would like to participate in voluntary and completed informed consent; Do not have sinus surgery; No sensitivity to common antibiotics or herbal remedies; Not pregnant or Plan to become pregnant; No immune deficiency (AIDS, diabetes or transplant); No acute respiratory disease in 7 days; Not have complicated acute sinusitis like an abscess; Not have acute symptoms such as severe pain or pressure, fever and purulent discharge; No ocular or brain complication of Sinusitis; No previous use of antibiotics in 7 days; Not use systemic corticosteroids in the last three months; Not any mental or psychological problem that cannot collaborate in projects. Exclusion criteria: Any type of serious complication or sensitivity to prescription drugs in this study; Pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
SNOT-22. Timepoint: before/after (after1 month). Method of measurement: fill questionnaire.

Secondary

MeasureTime frame
VAS )visual analog scale). Timepoint: before, after(after 1 month). Method of measurement: Self-assessment questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahboobeh Abrishamkar

Traditional Medicine Faculty of Ardakan, Shahid Sadoughei University of Medical Sciences

m_abrishamkar@tums.ac.ir; m_abrishmakar@yahoo.com; dr.abrishamkar@gmail.com+98 35 2723 8917

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026